CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results

Bulletin Express

Yesterday

CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month period ended 31 March 2026. The meeting will also address the formal release of the first-quarter report.

The announcement, dated 16 April 2026, lists the current board composition as follows: Executive Directors—Dr. Xuefeng Yu (Chairman), Dr. Shou Bai Chao and Ms. Jing Wang; Non-executive Director—Mr. Chi Shing Li; Independent Non-executive Directors—Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji.

No additional agenda items or financial figures were disclosed in the notice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1154636050"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154636050\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154636050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154636050","market":"hk","top_or_hot":-1,"title":"CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month period ended 31 March 2026. The meeting will also address the formal release of the first-quarter report.</p>\n<p>The announcement, dated 16 April 2026, lists the current board composition as follows: Executive Directors—Dr. Xuefeng Yu (Chairman), Dr. Shou Bai Chao and Ms. Jing Wang; Non-executive Director—Mr. Chi Shing Li; Independent Non-executive Directors—Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji.</p>\n<p>No additional agenda items or financial figures were disclosed in the notice.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-16 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month period ended 31 March 2026. The meeting will also address the formal release of the first-quarter report.</p>\n<p>The announcement, dated 16 April 2026, lists the current board composition as follows: Executive Directors—Dr. Xuefeng Yu (Chairman), Dr. Shou Bai Chao and Ms. Jing Wang; Non-executive Director—Mr. Chi Shing Li; Independent Non-executive Directors—Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji.</p>\n<p>No additional agenda items or financial figures were disclosed in the notice.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1154636050","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154636050","pubTimestamp":1776328982,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"CANSINOBIO计划于4月28日召开董事会批准2026年第一季度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) has notified the market that its board of directors will convene on 28 April 2026 to review and approve the consolidated financial results for the three‐month period ended 31 March 2026. The meeting will also address the formal release of the first-quarter report.\nThe announcement, dated 16 April 2026, lists the current board composition as follows: Executive Directors—Dr. Xuefeng Yu (Chairman), Dr. Shou Bai Chao and Ms. Jing Wang; Non-executive Director—Mr. Chi Shing Li; Independent Non-executive Directors—Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji.\nNo additional agenda items or financial figures were disclosed in the notice.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}